as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,246.0
Change
-0.2 (-0.02%)
Open
₹1,247.5
Prev. Close
₹1,246.2
Day High
₹1,259.6
Day Low
₹1,216.6
Volume Analysis
Traded
538,647
Delivered
103,660
Delivery %
19.24%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (22.0%)
Weaknesses (1)
- •Below-average fundamentals quality score (49/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,307.86 | ₹1,283.73 | ₹1,264.86 | ₹1,240.73 | ₹1,221.86 | ₹1,197.73 | ₹1,178.86 |
| Fibonacci | ₹1,283.73 | ₹1,267.3 | ₹1,257.16 | ₹1,240.73 | ₹1,224.3 | ₹1,214.16 | ₹1,197.73 |
| Camarilla | ₹1,257.83 | ₹1,253.88 | ₹1,249.94 | ₹1,240.73 | ₹1,242.06 | ₹1,238.12 | ₹1,234.18 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+2.23%
1 Month
+13.82%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
13.96%
Net margin 11.34% × asset turnover 0.68x × equity multiplier 1.81x
Company Overview
Sector
Healthcare
Market Cap
₹15,118 Cr
P/E (TTM)
60.6
ROE
15.6%
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Molbio Diagnostics Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (95/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%); below-average fundamentals quality score (49/100).
TopFund Score — Fundamentals Quality
49/100 — WeakData confidence: 69/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 148 days to 116 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Intimation of Analysts/Investors Meeting under Regulation 30 of the SEBI (LODR) Regulations, 2015, scheduled to be held on Tuesday, September ....
Pursuant to Regulation 30 of the SEBI(LODR),2015, Please find attached herewith the Transcripts of the Earning call held on September 08,2026 in relation to the …
Molbio Diagnostics’ CIN changed to L33125GA2000PLC002909; MCA status updated to listed after NSE/BSE listing.
Audio recording of Q1 FY2027 earnings call is available on Molbio’s website.
Investor Presentation on Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales + | 100 | 561 | 408 |
| Expenses + | 116 | 402 | 308 |
| Operating Profit | -16 | 159 | 101 |
| OPM % | -16.0% | 28.0% | 25.0% |
| Other Income + | 1 | 5 | 3 |
| Interest | 4 | 12 | 11 |
| Depreciation | 12 | 20 | 17 |
| Profit before tax | -31 | 132 | 76 |
| Tax % | -23.0% | 27.0% | 31.0% |
| Net Profit + | -24 | 96 | 53 |
| EPS in Rs | -11 | 8 | 5 |
| Raw PDF | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales + | 837 | 1,020 | 1,446 |
| Expenses + | 602 | 760 | 1,126 |
| Operating Profit | 234 | 260 | 320 |
| OPM % | 28.0% | 26.0% | 22.0% |
| Other Income + | -49 | -4 | 9 |
| Interest | 14 | 18 | 33 |
| Depreciation | 41 | 45 | 64 |
| Profit before tax | 130 | 194 | 231 |
| Tax % | 36.0% | 29.0% | 29.0% |
| Net Profit + | 84 | 139 | 164 |
| EPS in Rs | 452 | 64 | 15 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Reserves | 821 | 966 | 1,158 |
| Borrowings + | 184 | 147 | 450 |
| Other Liabilities + | 211 | 346 | 496 |
| Total Liabilities | 1,218 | 1,461 | 2,115 |
| Fixed Assets + | 289 | 290 | 536 |
| CWIP | 2 | 27 | 11 |
| Investments | 6 | 46 | 6 |
| Other Assets + | 921 | 1,099 | 1,562 |
| Total Assets | 1,218 | 1,461 | 2,115 |
| Equity Capital | 2 | 2 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from Operating Activity + | 10 | 287 | 50 |
| Cash from Investing Activity + | -45 | -123 | -54 |
| Cash from Financing Activity + | -32 | -26 | 276 |
| Net Cash Flow | -67 | 138 | 273 |
| CFO/OP | 23 | 141 | 38 |
| Free Cash Flow | -7 | 232 | 1 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Aug 2026 | |
|---|---|
| Public | 40.83% |
| Promoters | 41.29% |
| Government | 0.02% |
| FII | 1.51% |
| DII | 16.36% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Molbio Diagnostics Ltd (this stock) | 15,118 | 60.6 | — | 15.6% |
| Natco Pharma Ltd. | 15,033 | 13.1 | 1.63 | 17.1% |
| Marksans Pharma Limited | 15,269 | 29.6 | 5.05 | 15.2% |
| Syngene International Ltd | 15,287 | 51.6 | 3.16 | 7.78% |
| Vijaya Diagnostic Cen Ltd | 15,590 | 83.2 | 16.28 | 18.3% |
| Dr Agarwals Health Care L | 15,686 | 106.0 | 7.75 | 5.99% |
| Indegene Limited | 14,319 | 34.4 | 4.57 | 14.4% |
Which Mutual Funds Hold Molbio Diagnostics Ltd?
Frequently Asked Questions about Molbio Diagnostics Ltd
Molbio Diagnostics Ltd (MOLBIO) closed at ₹1,246.0 on NSE on 25 September 2026, down 0.2 (0.02%) from the previous close.
Molbio Diagnostics Ltd trades on the NSE (National Stock Exchange of India) under the symbol MOLBIO.
Molbio Diagnostics Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 60.6.
Molbio Diagnostics Ltd has a dividend yield of 0.0%.
Molbio Diagnostics Ltd's 52-week high is ₹1,687.0 and its 52-week low is ₹926.0.
Molbio Diagnostics Ltd has a market capitalisation of ₹15,118 crore.
Molbio Diagnostics Ltd has a TopFund Quality Score of 49/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Molbio Diagnostics Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.